These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35850403)

  • 1. Real-world medication persistence among HIV-1 patients initiating integrase inhibitor-based antiretroviral therapy in Japan.
    Wang X; Schmerold L; Naito T
    J Infect Chemother; 2022 Nov; 28(11):1464-1470. PubMed ID: 35850403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world adherence and persistence for newly-prescribed HIV treatment: single versus multiple tablet regimen comparison among US medicaid beneficiaries.
    Cohen J; Beaubrun A; Bashyal R; Huang A; Li J; Baser O
    AIDS Res Ther; 2020 Apr; 17(1):12. PubMed ID: 32238169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Stribild®): a review of its use in the management of HIV-1 infection in adults.
    Perry CM
    Drugs; 2014 Jan; 74(1):75-97. PubMed ID: 24338165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of cardiometabolic outcomes among people living with HIV-1 initiated on integrase strand transfer inhibitor versus non-integrase strand transfer inhibitor antiretroviral therapies: a retrospective analysis of insurance claims in the United States.
    Rebeiro PF; Emond B; Rossi C; Bookhart BK; Shah A; Caron-Lapointe G; Lafeuille MH; Donga P
    J Int AIDS Soc; 2023 Jun; 26(6):e26123. PubMed ID: 37306118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients.
    Gianotti N; Poli A; Nozza S; Galli L; Galizzi N; Ripa M; Merli M; Carbone A; Spagnuolo V; Lazzarin A; Castagna A
    BMC Infect Dis; 2017 Nov; 17(1):723. PubMed ID: 29145807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world medication persistence with single versus multiple tablet regimens for HIV-1 treatment.
    Sweet D; Song J; Zhong Y; Signorovitch J
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19537. PubMed ID: 25394046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment-related early discontinuations and adverse events among newly diagnosed people living with HIV initiating integrase inhibitors in a real-world setting.
    Rolle CP; Castano J; Nguyen V; Patel K; Hinestrosa F; DeJesus E
    Antivir Ther; 2023 Feb; 28(2):13596535231163703. PubMed ID: 36896821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study.
    Squires K; Kityo C; Hodder S; Johnson M; Voronin E; Hagins D; Avihingsanon A; Koenig E; Jiang S; White K; Cheng A; Szwarcberg J; Cao H
    Lancet HIV; 2016 Sep; 3(9):e410-e420. PubMed ID: 27562742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide in the United States.
    Emond B; Rossi C; Côté-Sergent A; Bookhart B; Anderson D; Lefebvre P; Lafeuille MH; Donga P
    Curr Med Res Opin; 2022 Feb; 38(2):287-298. PubMed ID: 34812097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Effectiveness of Rilpivirine-Based Single-Tablet Regimens in a Seven-Year, Two-Center Observational Cohort of People Living with HIV.
    Taramasso L; Lo Caputo S; Magnasco L; Briano F; Poliseno M; Bruno SR; Ferrara S; Pincino R; Sarteschi G; Beltramini S; Sasso E; Mora S; Giacomini M; Bassetti M; Di Biagio A
    AIDS Res Hum Retroviruses; 2022 Jun; 38(6):472-479. PubMed ID: 35172617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data.
    Mills A; Crofoot G; Ortiz R; Rashbaum B; Towner W; Ward D; Brinson C; Kulkarni R; Garner W; Ebrahimi R; Cao H; Cheng A; Szwarcberg J
    HIV Clin Trials; 2014; 15(2):51-6. PubMed ID: 24710918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens.
    Raffi F; Esser S; Nunnari G; Pérez-Valero I; Waters L
    HIV Med; 2016 Oct; 17 Suppl 5():3-16. PubMed ID: 27714978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial.
    Maggiolo F; Rizzardini G; Raffi F; Pulido F; Mateo-Garcia MG; Molina JM; Ong E; Shao Y; Piontkowsky D; Das M; McNicholl I; Haubrich R
    Lancet HIV; 2019 Oct; 6(10):e655-e666. PubMed ID: 31578954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate.
    Margot N; Cox S; Das M; McCallister S; Miller MD; Callebaut C
    Antivir Ther; 2017; 22(5):443-446. PubMed ID: 28076335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis.
    Inciarte A; Leal L; González E; León A; Lucero C; Mallolas J; Torres B; Laguno M; Rojas J; Martínez-Rebollar M; González-Cordón A; Cruceta A; Arnaiz JA; Gatell JM; García F;
    J Antimicrob Chemother; 2017 Oct; 72(10):2857-2861. PubMed ID: 29091217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No progression of subclinical atherosclerosis in HIV-infected patients starting an initial regimen including tenofovir alafenamide/emtricitabine plus raltegravir, dolutegravir or elvitegravir/cobicistat during a two-year follow-up.
    Calza L; Borderi M; Colangeli V; Borioni A; Coladonato S; Granozzi B; Viale P
    Infect Dis (Lond); 2020 Apr; 52(4):249-256. PubMed ID: 31876437
    [No Abstract]   [Full Text] [Related]  

  • 17. Durability of single tablet regimen for patients with HIV infection in Southern Taiwan: data from a real-world setting.
    Chang HM; Chou CH; Tsai HC
    BMC Infect Dis; 2022 Jan; 22(1):2. PubMed ID: 34983388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.
    Gaur AH; Kizito H; Prasitsueubsai W; Rakhmanina N; Rassool M; Chakraborty R; Batra J; Kosalaraksa P; Luesomboon W; Porter D; Shao Y; Myers M; Ting L; SenGupta D; Quirk E; Rhee MS
    Lancet HIV; 2016 Dec; 3(12):e561-e568. PubMed ID: 27765666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. INSTI-Based Initial Antiretroviral Therapy in Adults with HIV, the HIV Outpatient Study, 2007-2018.
    Mayer S; Rayeed N; Novak RM; Li J; Palella FJ; Buchacz K;
    AIDS Res Hum Retroviruses; 2021 Oct; 37(10):768-775. PubMed ID: 34030459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection.
    Greig SL; Deeks ED
    Drugs; 2015 Apr; 75(5):503-14. PubMed ID: 25698454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.